January 2014

Global Strategy for Diagnosis, Management and

Prevention of COPD (2014 update)
Publications Reviewed by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) Science Committee

The process to produce the 2014 update included a Pub Med search using
search fields established by the Committee: COPD: Abstract available,
Publication date from 2012/07/01 to 2013/12/31, Humans, Clinical Trial,
Randomized Controlled Trial, Meta-Analysis, Systematic Reviews, Adult: 19+
years.

1. Aaron SD, Vandemheen KL, Maltais F, et al. TNFalpha antagonists for
acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax
2013;68:142-8.
2. Adler D, Perrig S, Takahashi H, et al. Polysomnography in stable COPD
under non-invasive ventilation to reduce patient-ventilator asynchrony and
morning breathlessness. Sleep Breath 2012;16:1081-90.
3. Agostini P, Naidu B, Cieslik H, et al. Effectiveness of incentive spirometry
in patients following thoracotomy and lung resection including those at high risk
for developing pulmonary complications. Thorax 2013;68:580-5.
4. Agusti A, Soler JJ, Molina J, et al. Is the CAT questionnaire sensitive to
changes in health status in patients with severe COPD exacerbations? Copd
2012;9:492-8.
5. Al-shair K, Muellerova H, Yorke J, et al. Examining fatigue in COPD:
development, validity and reliability of a modified version of FACIT-F scale.
Health Qual Life Outcomes 2012;10:100.
6. Albers F, Shaikh A, Iqbal A. Design, rationale, and baseline demographics
of SEARCH I: a prospective cluster-randomized study. Int J Chron Obstruct
Pulmon Dis 2012;7:437-45.
7. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a
phenotypic characteristic of established chronic obstructive pulmonary disease.
Thorax 2012;67:701-8.
8. Albert RK, Connett J, Curtis JL, et al. Mannose-binding lectin deficiency
and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron
Obstruct Pulmon Dis 2012;7:767-77.
9. Alexandre BM, Charro N, Blonder J, et al. Profiling the erythrocyte
membrane proteome isolated from patients diagnosed with chronic obstructive
pulmonary disease. J Proteomics 2012;76 Spec No.:259-69.
10. Alexopoulos GS, Kiosses DN, Sirey JA, et al. Personalised intervention for
people with depression and severe COPD. Br J Psychiatry 2013;202:235-6.
11. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled
corticosteroid, demonstrates prolonged lung absorption kinetics in man
compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013;52:37-
42.
12. Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term
prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI
study. Chest 2012.
13. Andreas S, Chenot JF, Diebold R, Peachey S, Mann K. Effectiveness of
varenicline as an aid to smoking cessation in primary care: an observational
study. Eur Addict Res 2013;19:47-54.
14. Antoniades NC, Rochford PD, Pretto JJ, et al. Pilot study of remote
telemonitoring in COPD. Telemed J E Health 2012;18:634-40.
15. Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K.
Identifying patients at risk of late recovery (>/= 8 days) from acute exacerbation
of chronic bronchitis and COPD. Respir Med 2012;106:1258-67.
16. Arievich H, Overend T, Renard D, et al. A novel model-based approach for
dose determination of glycopyrronium bromide in COPD. BMC Pulm Med
2012;12:74.
17. Armstrong HF, Gonzalez-Costello J, Jorde UP, et al. The effect of lung
volume reduction surgery on chronotropic incompetence. Respir Med
2012;106:1389-95.
18. Bahr TM, Hughes GJ, Armstrong M, et al. Peripheral blood mononuclear
cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell
Mol Biol 2013;49:316-23.
19. Bateman E, Feldman G, Kilbride S, et al. Efficacy and safety of the long-
acting muscarinic antagonist GSK233705 delivered once daily in patients with
COPD. Clin Respir J 2012;6:248-57.
20. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with
QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J
2013;42:1484-94.
21. Baumann HJ, Kluge S, Rummel K, et al. Low intensity, long-term
outpatient rehabilitation in COPD: a randomised controlled trial. Respir Res
2012;13:86.
22. Bausewein C, Jolley C, Reilly C, et al. Development, effectiveness and
cost-effectiveness of a new out-patient Breathlessness Support Service: study
protocol of a phase III fast-track randomised controlled trial. BMC Pulm Med
2012;12:58.
23. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237
improves exercise tolerance from the first dose in patients with COPD: the
GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-13.
24. Benzo R, Vickers K, Ernst D, Tucker S, McEvoy C, Lorig K. Development
and feasibility of a self-management intervention for chronic obstructive
pulmonary disease delivered with motivational interviewing strategies. J
Cardiopulm Rehabil Prev 2013;33:113-23.
25. Bertoletti L, Quenet S, Laporte S, et al. Pulmonary embolism and 3-month
outcomes in 4036 patients with venous thromboembolism and chronic
obstructive pulmonary disease: data from the RIETE registry. Respir Res
2013;14:75.
26. Bhatt SP, Luqman-Arafath TK, Gupta AK, et al. Volitional pursed lips
breathing in patients with stable chronic obstructive pulmonary disease improves
exercise capacity. Chron Respir Dis 2013;10:5-10.
27. Bihari S, Bersten AD. Chronic heart failure modifies the response to
positive end-expiratory pressure in patients with chronic obstructive pulmonary
disease. J Crit Care 2012;27:639-46.
28. Bischoff EW, Akkermans R, Bourbeau J, van Weel C, Vercoulen JH,
Schermer TR. Comprehensive self management and routine monitoring in
chronic obstructive pulmonary disease patients in general practice: randomised
controlled trial. Bmj 2012;345:e7642.
29. Bjerk SM, Edgington BD, Rector TS, Kunisaki KM. Supplemental vitamin
D and physical performance in COPD: a pilot randomized trial. Int J Chron
Obstruct Pulmon Dis 2013;8:97-104.
30. Bjermer L, Bengtsson T, Jorup C, Lotvall J. Local and systemic effects of
inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med
2013;107:84-90.
31. Bleecker ER, Meyers DA, Bailey WC, et al. ADRB2 polymorphisms and
budesonide/formoterol responses in COPD. Chest 2012;142:320-8.
32. Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of
once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients
with chronic obstructive pulmonary disease: a randomized, three-way,
incomplete block, crossover study. Clin Ther 2012;34:1655-66 e5.
33. Braunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H.
Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic
pulmonary fibrosis patients. Respiration 2013;85:319-25.
34. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung
cancer risk: a pooled analysis from the International Lung Cancer Consortium.
Am J Epidemiol 2012;176:573-85.
35. Briones Claudett KH, Briones Claudett M, Chung Sang Wong M, et al.
Noninvasive mechanical ventilation with average volume assured pressure
support (AVAPS) in patients with chronic obstructive pulmonary disease and
hypercapnic encephalopathy. BMC Pulm Med 2013;13:12.
36. Bronstad E, Rognmo O, Tjonna AE, et al. High-intensity knee extensor
training restores skeletal muscle function in COPD patients. Eur Respir J
2012;40:1130-6.
37. Budulac SE, Postma DS, Hiemstra PS, et al. Multidrug resistance-
associated protein 1 and lung function decline with or without long-term
corticosteroids treatment in COPD. Eur J Pharmacol 2012;696:136-42.
38. Buggeskov KB, Wetterslev J, Secher NH, Andersen LW, Jonassen T,
Steinbruchel DA. Pulmonary perfusion with oxygenated blood or custodiol HTK
solution during cardiac surgery for postoperative pulmonary function in COPD
patients: a trial protocol for the randomized, clinical, parallel group, assessor and
data analyst blinded Pulmonary Protection Trial. Trials 2013;14:30.
39. Buhl R, Welte T, Vogelmeier C, et al. [Early treatment of COPD with
tiotropium]. Pneumologie 2012;66:589-95.
40. Burgel PR, Escamilla R, Perez T, et al. Impact of comorbidities on COPD-
specific health-related quality of life. Respir Med 2013;107:233-41.
41. Butcher SJ, Pikaluk BJ, Chura RL, Walkner MJ, Farthing JP, Marciniuk
DD. Associations between isokinetic muscle strength, high-level functional
performance, and physiological parameters in patients with chronic obstructive
pulmonary disease. Int J Chron Obstruct Pulmon Dis 2012;7:537-42.
42. Canto ND, Ribeiro JP, Neder JA, Chiappa GR. Addition of tiotropium to
formoterol improves inspiratory muscle strength after exercise in COPD. Respir
Med 2012;106:1404-12.
43. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index
and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS
One 2012;7:e43892.
44. Cartwright M, Hirani SP, Rixon L, et al. Effect of telehealth on quality of life
and psychological outcomes over 12 months (Whole Systems Demonstrator
telehealth questionnaire study): nested study of patient reported outcomes in a
pragmatic, cluster randomised controlled trial. Bmj 2013;346:f653.
45. Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of
indacaterol in COPD patients under regular treatment with indacaterol. Respir
Med 2013;107:107-11.
46. Celli BR, Decramer M, Lystig T, Kesten S, Tashkin DP. Longitudinal
inspiratory capacity changes in chronic obstructive pulmonary disease. Respir
Res 2012;13:66.
47. Chandra D, Wise RA, Kulkarni HS, et al. Optimizing the 6-min walk test as
a measure of exercise capacity in COPD. Chest 2012;142:1545-52.
48. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic
obstructive pulmonary disease and cognitive impairment on health outcomes in
older adults. J Am Geriatr Soc 2012;60:1839-46.
49. Chau JP, Lee DT, Yu DS, et al. A feasibility study to investigate the
acceptability and potential effectiveness of a telecare service for older people
with chronic obstructive pulmonary disease. Int J Med Inform 2012;81:674-82.
50. Chin RC, Guenette JA, Cheng S, et al. Does the respiratory system limit
exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care
Med 2013;187:1315-23.
51. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists
for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2012;9:CD009157.
52. Come CE, Diaz AA, Curran-Everett D, et al. Characterizing functional lung
heterogeneity in COPD using reference equations for CT scan-measured lobar
volumes. Chest 2013;143:1607-17.
53. Constantin D, Menon MK, Houchen-Wolloff L, et al. Skeletal muscle
molecular responses to resistance training and dietary supplementation in
COPD. Thorax 2013;68:625-33.
54. Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Efficacy of
indacaterol 75 mug versus fixed-dose combinations of formoterol-budesonide or
salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct
Pulmon Dis 2012;7:415-20.
55. Coventry PA, Bower P, Keyworth C, et al. The effect of complex
interventions on depression and anxiety in chronic obstructive pulmonary
disease: systematic review and meta-analysis. PLoS One 2013;8:e60532.
56. Cracco C, Fartoukh M, Prodanovic H, et al. Safety of performing fiberoptic
bronchoscopy in critically ill hypoxemic patients with acute respiratory failure.
Intensive Care Med 2013;39:45-52.
57. Cross JL, Elender F, Barton G, et al. Evaluation of the effectiveness of
manual chest physiotherapy techniques on quality of life at six months post
exacerbation of COPD (MATREX): a randomised controlled equivalence trial.
BMC Pulm Med 2012;12:33.
58. De Backer LA, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, De
Backer W. The acute effect of budesonide/formoterol in COPD: a multi-slice
computed tomography and lung function study. Eur Respir J 2012;40:298-305.
59. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM,
Frances JF, Lozano PV, Bellon-Cano JM. Chronic obstructive pulmonary disease
as a cardiovascular risk factor. Results of a case-control study (CONSISTE
study). Int J Chron Obstruct Pulmon Dis 2012;7:679-86.
60. de Matos Cavalcante AG, de Bruin PF, de Bruin VM, et al. Melatonin
reduces lung oxidative stress in patients with chronic obstructive pulmonary
disease: a randomized, double-blind, placebo-controlled study. J Pineal Res
2012;53:238-44.
61. de Miguel-Diez J, Jimenez-Garcia R, Hernandez-Barrera V, et al. Trends
in hospital admissions for acute exacerbation of COPD in Spain from 2006 to
2010. Respir Med 2013;107:717-23.
62. de-Torres JP, Casanova C, Marin JM, et al. Exploring the impact of
screening with low-dose CT on lung cancer mortality in mild to moderate COPD
patients: a pilot study. Respir Med 2013;107:702-7.
63. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
Effects of long-acting bronchodilators in COPD patients according to COPD
severity and ICS use. Respir Med 2013;107:223-32.
64. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of
umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir
Physiol Neurobiol 2013;185:393-9.
65. Decramer M, Rossi A, Lawrence D, McBryan D. Indacaterol therapy in
patients with COPD not receiving other maintenance treatment. Respir Med
2012;106:1706-14.
66. Deneckere S, Euwema M, Van Herck P, et al. Care pathways lead to
better teamwork: results of a systematic review. Soc Sci Med 2012;75:264-8.
67. Di YP, Zhao J, Harper R. Cigarette smoke induces MUC5AC protein
expression through the activation of Sp1. J Biol Chem 2012;287:27948-58.
68. Dodd JW, Marns PL, Clark AL, et al. The COPD Assessment Test (CAT):
short- and medium-term response to pulmonary rehabilitation. Copd 2012;9:390-
4.
69. Dolmage TE, Janaudis-Ferreira T, Hill K, Price S, Brooks D, Goldstein RS.
Arm elevation and coordinated breathing strategies in patients with COPD. Chest
2013;144:128-35.
70. Donaldson GC, Mullerova H, Locantore N, et al. Factors associated with
change in exacerbation frequency in COPD. Respir Res 2013;14:79.
71. Donaldson GC, Seemungal TA, Hurst JR, Wedzicha JA. Detrended
fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD.
Eur Respir J 2012;40:1123-9.
72. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative
safety of inhaled medications in patients with chronic obstructive pulmonary
disease: systematic review and mixed treatment comparison meta-analysis of
randomised controlled trials. Thorax 2013;68:48-56.
73. Doyle C, Dunt D, Ames D, Selvarajah S. Managing mood disorders in
patients attending pulmonary rehabilitation clinics. Int J Chron Obstruct Pulmon
Dis 2013;8:15-20.
74. Edwards L, Perrin K, Williams M, Weatherall M, Beasley R. Randomised
controlled crossover trial of the effect on PtCO2 of oxygen-driven versus air-
driven nebulisers in severe chronic obstructive pulmonary disease. Emerg Med J
2012;29:894-8.
75. Edwards L, Shirtcliffe P, Wadsworth K, et al. Use of nebulised magnesium
sulphate as an adjuvant in the treatment of acute exacerbations of COPD in
adults: a randomised double-blind placebo-controlled trial. Thorax 2013;68:338-
43.
76. Egan C, Deering BM, Blake C, et al. Short term and long term effects of
pulmonary rehabilitation on physical activity in COPD. Respir Med
2012;106:1671-9.
77. Ege MR, Guray U, Guray Y, et al. Acute heart failure with accompanying
chronic obstructive pulmonary disease: should we focus on beta blockers? Herz
2012;37:796-800.
78. Engelen MP, De Castro CL, Rutten EP, Wouters EF, Schols AM, Deutz
NE. Enhanced anabolic response to milk protein sip feeding in elderly subjects
with COPD is associated with a reduced splanchnic extraction of multiple amino
acids. Clin Nutr 2012;31:616-24.
79. Ewert R, Glaser S, Winkler J, et al. [Cardiopulmonary Exercise Testing
(CPET) in severe COPD--a multicentre comparison of two test protocols].
Pneumologie 2012;66:402-7.
80. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-Day safety and
tolerability of umeclidinium in combination with vilanterol in COPD: a randomized
placebo-controlled trial. Pulm Pharmacol Ther 2012;25:465-71.
81. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation
for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2012;12:CD000998.
82. Fridlender ZG, Arish N, Laxer U, et al. Randomized controlled crossover
trial of a new oscillatory device as add-on therapy for COPD. Copd 2012;9:603-
10.
83. Fulton AS, Hill AM, Williams MT, et al. Feasibility of omega-3 fatty acid
supplementation as an adjunct therapy for people with chronic obstructive
pulmonary disease: study protocol for a randomized controlled trial. Trials
2013;14:107.
84. Furness T, Bate N, Welsh L, Naughton G, Lorenzen C. Efficacy of a
whole-body vibration intervention to effect exercise tolerance and functional
performance of the lower limbs of people with chronic obstructive pulmonary
disease. BMC Pulm Med 2012;12:71.
85. Gagnon P, Bussieres JS, Ribeiro F, et al. Influences of spinal anesthesia
on exercise tolerance in patients with chronic obstructive pulmonary disease. Am
J Respir Crit Care Med 2012;186:606-15.
86. Gagnon P, Saey D, Provencher S, et al. Walking exercise response to
bronchodilation in mild COPD: a randomized trial. Respir Med 2012;106:1695-
705.
87. Galera R, Casitas R, Martinez E, et al. Exercise oxygen flow titration
methods in COPD patients with respiratory failure. Respir Med 2012;106:1544-
50.
88. Gao P, Gibson PG, Zhang J, et al. The safety of sputum induction in
adults with acute exacerbation of COPD. Clin Respir J 2013;7:101-9.
89. Garcia-Polo C, Alcazar-Navarrete B, Ruiz-Iturriaga LA, et al. Factors
associated with high healthcare resource utilisation among COPD patients.
Respir Med 2012;106:1734-42.
90. Garner DJ, Berlowitz DJ, Douglas J, et al. Home mechanical ventilation in
Australia and New Zealand. Eur Respir J 2013;41:39-45.
91. Giavedoni S, Deans A, McCaughey P, Drost E, MacNee W, Rabinovich
RA. Neuromuscular electrical stimulation prevents muscle function deterioration
in exacerbated COPD: a pilot study. Respir Med 2012;106:1429-34.
92. Gloeckl R, Halle M, Kenn K. Interval versus continuous training in lung
transplant candidates: a randomized trial. J Heart Lung Transplant 2012;31:934-
41.
93. Goossens LM, Utens CM, Smeenk FW, et al. Cost-effectiveness of early
assisted discharge for COPD exacerbations in The Netherlands. Value Health
2013;16:517-28.
94. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of
indacaterol 75 mug once-daily on dyspnea and health status: results of two
double-blind, placebo-controlled 12-week studies. Copd 2012;9:629-36.
95. Grau M, Barr RG, Lima JA, et al. Percent emphysema and right ventricular
structure and function: the Multi-Ethnic Study of Atherosclerosis-Lung and Multi-
Ethnic Study of Atherosclerosis-Right Ventricle Studies. Chest 2013;144:136-44.
96. Gruffydd-Jones K, Marsden HC, Holmes S, et al. Utility of COPD
Assessment Test (CAT) in primary care consultations: a randomised controlled
trial. Prim Care Respir J 2013;22:37-43.
97. Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in
patients hospitalized for chronic obstructive pulmonary disease: a prospective
observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis
2012;7:571-6.
98. Guenette JA, Webb KA, O'Donnell DE. Effect of fluticasone/salmeterol
combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
Respir Med 2013;107:708-16.
99. Guerin JC, Roche N, Vicaut E, et al. [Early detection of COPD in primary
care: which tools?]. Rev Mal Respir 2012;29:889-97.
100. Guerrero A, Montserrat JM, Farre R, Masa F, Duran J, Embid C.
Automatic CPAP performance in patients with sleep apnea plus COPD. Copd
2012;9:382-9.
101. Gunawardena KA, Gullstrand H, Perrett J. Pharmacokinetics and safety of
AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients
with COPD. Int J Clin Pharmacol Ther 2013;51:288-304.
102. Gupta PK, Gupta H, Kaushik M, et al. Predictors of pulmonary
complications after bariatric surgery. Surg Obes Relat Dis 2012;8:574-81.
103. Gurgun A, Deniz S, Argin M, Karapolat H. Effects of nutritional
supplementation combined with conventional pulmonary rehabilitation in muscle-
wasted chronic obstructive pulmonary disease: a prospective, randomized and
controlled study. Respirology 2013;18:495-500.
104. Guvenc TS, Erer HB, Kul S, et al. Right ventricular morphology and
function in chronic obstructive pulmonary disease patients living at high altitude.
Heart Lung Circ 2013;22:31-7.
105. Hagedorn C, Kassner F, Banik N, Ntampakas P, Fielder K. Influence of
salmeterol/fluticasone via single versus separate inhalers on exacerbations in
severe/very severe COPD. Respir Med 2013;107:542-9.
106. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive
pulmonary disease: a systematic review and meta-analysis of randomized
placebo-controlled trials. BMC Pulm Med 2013;13:26.
107. Hansel NN, Ruczinski I, Rafaels N, et al. Genome-wide study identifies
two loci associated with lung function decline in mild to moderate COPD. Hum
Genet 2013;132:79-90.
108. Hansel NN, Washko GR, Foreman MG, et al. Racial differences in CT
phenotypes in COPD. Copd 2013;10:20-7.
109. Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O.
Indacaterol improves daily physical activity in patients with chronic obstructive
pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:1-5.
110. Haynes JM. Randomized controlled trial of a breath-activated nebulizer in
patients with exacerbation of COPD. Respir Care 2012;57:1385-90.
111. Henderson C, Knapp M, Fernandez JL, et al. Cost effectiveness of
telehealth for patients with long term conditions (Whole Systems Demonstrator
telehealth questionnaire study): nested economic evaluation in a pragmatic,
cluster randomised controlled trial. Bmj 2013;346:f1035.
112. Hersh CP, Washko GR, Estepar RS, et al. Paired inspiratory-expiratory
chest CT scans to assess for small airways disease in COPD. Respir Res
2013;14:42.
113. Ho CF, Maa SH, Shyu YI, Lai YT, Hung TC, Chen HC. Effectiveness of
paced walking to music at home for patients with COPD. Copd 2012;9:447-57.
114. Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of
bacteria by both alveolar and monocyte-derived macrophages in chronic
obstructive pulmonary disease subjects. Respirology 2012;17:802-7.
115. Hogg L, Garrod R, Thornton H, McDonnell L, Bellas H, White P.
Effectiveness, attendance, and completion of an integrated, system-wide
pulmonary rehabilitation service for COPD: prospective observational study.
Copd 2012;9:546-54.
116. Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2012;10:CD008250.
117. Holmgaard DB, Mygind LH, Titlestad IL, et al. Serum vitamin D in patients
with chronic obstructive lung disease does not correlate with mortality--results
from a 10-year prospective cohort study. PLoS One 2013;8:e53670.
118. Hoogendoorn M, Al MJ, Beeh KM, et al. Cost-effectiveness of tiotropium
versus salmeterol: the POET-COPD trial. Eur Respir J 2013;41:556-64.
119. Horita N, Miyazawa N, Morita S, et al. Long-acting beta-agonists reduce
mortality of patients with severe and very severe chronic obstructive pulmonary
disease: a propensity score matching study. Respir Res 2013;14:62.
120. Huang D, Yang L, Liu Y, et al. Functional polymorphisms in
NFkappaB1/IkappaBalpha predict risks of chronic obstructive pulmonary disease
and lung cancer in Chinese. Hum Genet 2013;132:451-60.
121. Idrees M, Koniski ML, Taright S, et al. Management of chronic obstructive
pulmonary disease in the Middle East and North Africa: results of the BREATHE
study. Respir Med 2012;106 Suppl 2:S33-44.
122. Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, et
al. Prevalence and characteristics of three clinical phenotypes of chronic
obstructive pulmonary disease (COPD). Respir Med 2013;107:724-31.
123. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia
related mortality in patients with COPD treated with fixed combinations of inhaled
corticosteroid and long acting beta2 agonist: observational matched cohort study
(PATHOS). Bmj 2013;346:f3306.
124. Janssens L, Brumagne S, McConnell AK, et al. Proprioceptive changes
impair balance control in individuals with chronic obstructive pulmonary disease.
PLoS One 2013;8:e57949.
125. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway
inflammation in chronic obstructive pulmonary disease: a systematic review and
meta-analysis. Int J Chron Obstruct Pulmon Dis 2012;7:587-95.
126. Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT. Safety and
efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD
patients: a systematic review. Lung 2013;191:135-46.
127. Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD:
results from the Burden of Obstructive Lung Disease study. Eur Respir J
2013;41:548-55.
128. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status
scores with MRC grades in COPD: implications for the GOLD 2011 classification.
Eur Respir J 2013;42:647-54.
129. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily
aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J
2012;40:830-6.
130. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of
COPD and their relationship to COPD Assessment Test (CAT) scores. BMC
Pulm Med 2011;11:42.
131. Jurado Gamez B, Feu Collado N, Jurado Garcia JC, et al. Home
intervention and predictor variables for rehospitalization in chronic obstructive
pulmonary disease exacerbations. Arch Bronconeumol 2013;49:10-4.
132. Karakatsani A, Analitis A, Perifanou D, et al. Particulate matter air
pollution and respiratory symptoms in individuals having either asthma or chronic
obstructive pulmonary disease: a European multicentre panel study. Environ
Health 2012;11:75.
133. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285.
134. Katajisto M, Kupiainen H, Rantanen P, et al. Physical inactivity in COPD
and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis
2012;7:743-55.
135. Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability,
pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone
and in combination: a randomized crossover trial. PLoS One 2012;7:e50716.
136. Kelly JL, Elkin SL, Fluxman J, Polkey MI, Soljak MA, Hopkinson NS.
Breathlessness and skeletal muscle weakness in patients undergoing lung health
screening in primary care. Copd 2013;10:40-54.
137. Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237
versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur
Respir J 2012;40:1106-14.
138. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of
fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD.
Respir Med 2013;107:560-9.
139. Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of
blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2012;186:1238-47.
140. Kim J, Kim S, Kim HC, et al. Effects of consumer-centered u-health
service for the knowledge, skill, and attitude of the patients with chronic
obstructive pulmonary disease. Comput Inform Nurs 2012;30:661-71.
141. Kim SS, Seo JB, Lee HY, et al. Chronic obstructive pulmonary disease:
lobe-based visual assessment of volumetric CT by Using standard images--
comparison with quantitative CT and pulmonary function test in the COPDGene
study. Radiology 2013;266:626-35.
142. Kim V, Kretschman DM, Sternberg AL, DeCamp MM, Jr., Criner GJ.
Weight gain after lung reduction surgery is related to improved lung function and
ventilatory efficiency. Am J Respir Crit Care Med 2012;186:1109-16.
143. Kirby M, Svenningsen S, Owrangi A, et al. Hyperpolarized 3He and 129Xe
MR imaging in healthy volunteers and patients with chronic obstructive
pulmonary disease. Radiology 2012;265:600-10.
144. Kitaguchi Y, Fujimoto K, Komatsu Y, Hanaoka M, Honda T, Kubo K.
Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and
exercise tolerance in stable COPD patients treated with long-acting
bronchodilators. Respir Med 2013;107:394-400.
145. Klijn P, van Keimpema A, Legemaat M, Gosselink R, van Stel H.
Nonlinear exercise training in advanced chronic obstructive pulmonary disease is
superior to traditional exercise training. A randomized trial. Am J Respir Crit Care
Med 2013;188:193-200.
146. Kluge S, Braune SA, Engel M, et al. Avoiding invasive mechanical
ventilation by extracorporeal carbon dioxide removal in patients failing
noninvasive ventilation. Intensive Care Med 2012;38:1632-9.
147. Kosoglou T, Hubbell J, Xuan F, et al. Comparison of the systemic
bioavailability of mometasone furoate after oral inhalation from a mometasone
furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate
dry-powder inhaler in patients with chronic obstructive pulmonary disease. Int J
Chron Obstruct Pulmon Dis 2013;8:107-16.
148. Kruis AL, Boland MR, Schoonvelde CH, et al. RECODE: design and
baseline results of a cluster randomized trial on cost-effectiveness of integrated
COPD management in primary care. BMC Pulm Med 2013;13:17.
149. Kuna P, Ivanov Y, Trofimov VI, et al. Efficacy and safety of AZD3199 vs
formoterol in COPD: a randomized, double-blind study. Respir Res 2013;14:64.
150. Lacedonia D, Carpagnano GE, Aliani M, et al. Daytime PaO2 in OSAS,
COPD and the combination of the two (overlap syndrome). Respir Med
2013;107:310-6.
151. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of
chronic obstructive pulmonary disease, using the new GOLD classification: a
study of the general population. Am J Respir Crit Care Med 2012;186:975-81.
152. Larsson K, Janson C, Lisspers K, et al. Combination of
budesonide/formoterol more effective than fluticasone/salmeterol in preventing
exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J
Intern Med 2013;273:584-94.
153. Laserna E, Sibila O, Aguilar PR, et al. Hypocapnia and hypercapnia are
predictors for ICU admission and mortality in hospitalized patients with
community-acquired pneumonia. Chest 2012;142:1193-9.
154. Lee JS, Park DA, Hong Y, et al. Systematic review and meta-analysis of
prophylactic antibiotics in COPD and/or chronic bronchitis. Int J Tuberc Lung Dis
2013;17:153-62.
155. Leidy NK, Hamilton A, Becker K. Assessing patient report of function:
content validity of the Functional Performance Inventory-Short Form (FPI-SF) in
patients with chronic obstructive pulmonary disease (COPD). Int J Chron
Obstruct Pulmon Dis 2012;7:543-54.
156. Lellouche F, Pignataro C, Maggiore SM, et al. Short-term effects of
humidification devices on respiratory pattern and arterial blood gases during
noninvasive ventilation. Respir Care 2012;57:1879-86.
157. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional
glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary
disease: the REDUCE randomized clinical trial. Jama 2013;309:2223-31.
158. Li SY, Li JS, Wang MH, et al. Effects of comprehensive therapy based on
traditional Chinese medicine patterns in stable chronic obstructive pulmonary
disease: a four-center, open-label, randomized, controlled study. BMC
Complement Altern Med 2012;12:197.
159. Lin WC, Yuan SC, Chien JY, Weng SC, Chou MC, Kuo HW. The effects of
respiratory training for chronic obstructive pulmonary disease patients: a
randomised clinical trial. J Clin Nurs 2012;21:2870-8.
160. Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of
antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2012;186:716-23.
161. Londahl J, Swietlicki E, Rissler J, et al. Experimental determination of the
respiratory tract deposition of diesel combustion particles in patients with chronic
obstructive pulmonary disease. Part Fibre Toxicol 2012;9:30.
162. Lord VM, Hume VJ, Kelly JL, et al. Singing classes for chronic obstructive
pulmonary disease: a randomized controlled trial. BMC Pulm Med 2012;12:69.
163. Louvaris Z, Zakynthinos S, Aliverti A, et al. Heliox increases quadriceps
muscle oxygen delivery during exercise in COPD patients with and without
dynamic hyperinflation. J Appl Physiol (1985) 2012;113:1012-23.
164. MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF. Efficacy and safety
of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a
randomised clinical trial. Thorax 2013;68:738-45.
165. Magnussen H, Paggiaro P, Schmidt H, Kesten S, Metzdorf N, Maltais F.
Effect of combination treatment on lung volumes and exercise endurance time in
COPD. Respir Med 2012;106:1413-20.
166. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol
plus tiotropium in patients with COPD provides superior bronchodilation
compared with tiotropium alone: a randomised, double-blind comparison. Thorax
2012;67:781-8.
167. Mahler DA, Gifford AH, Waterman LA, et al. Effect of increased blood
levels of beta-endorphin on perception of breathlessness. Chest 2013;143:1378-
85.
168. Mainguy V, Girard D, Maltais F, et al. Effect of bisoprolol on respiratory
function and exercise capacity in chronic obstructive pulmonary disease. Am J
Cardiol 2012;110:258-63.
169. Martin-Lesende I, Orruno E, Bilbao A, et al. Impact of telemonitoring home
care patients with heart failure or chronic lung disease from primary care on
healthcare resource use (the TELBIL study randomised controlled trial). BMC
Health Serv Res 2013;13:118.
170. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol
(100/25; 200/25 mug) improves lung function in COPD: a randomised trial.
Respir Med 2013;107:550-9.
171. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al.
Prognostic value of bronchiectasis in patients with moderate-to-severe chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:823-31.
172. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, et al. Impact of
long-term treatment with low-dose inhaled corticosteroids on the bone mineral
density of chronic obstructive pulmonary disease patients: aggravating or
beneficial? Respirology 2013;18:147-53.
173. Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser
M. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with
COPD. Respir Med 2013;107:691-701.
174. McFarland C, Willson D, Sloan J, Coultas D. A randomized trial comparing
2 types of in-home rehabilitation for chronic obstructive pulmonary disease: a
pilot study. J Geriatr Phys Ther 2012;35:132-9.
175. McKeough ZJ, Bye PT, Alison JA. Arm exercise training in chronic
obstructive pulmonary disease: a randomised controlled trial. Chron Respir Dis
2012;9:153-62.
176. Mehta AJ, Schindler C, Perez L, et al. Acute respiratory health effects of
urban air pollutants in adults with different patterns of underlying respiratory
disease. Swiss Med Wkly 2012;142:w13681.
177. Mehta R, Kelleher D, Preece A, Hughes S, Crater G. Effect of verapamil
on systemic exposure and safety of umeclidinium and vilanterol: a randomized
and open-label study. Int J Chron Obstruct Pulmon Dis 2013;8:159-67.
178. Meijer CA, Kokje VB, van Tongeren RB, et al. An association between
chronic obstructive pulmonary disease and abdominal aortic aneurysm beyond
smoking: results from a case-control study. Eur J Vasc Endovasc Surg
2012;44:153-7.
179. Mentz RJ, Schmidt PH, Kwasny MJ, et al. The impact of chronic
obstructive pulmonary disease in patients hospitalized for worsening heart failure
with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail
2012;18:515-23.
180. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM.
Association of beta-blocker use and selectivity with outcomes in patients with
heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).
Am J Cardiol 2013;111:582-7.
181. Minet C, Vivodtzev I, Tamisier R, et al. Reduced six-minute walking
distance, high fat-free-mass index and hypercapnia are associated with
endothelial dysfunction in COPD. Respir Physiol Neurobiol 2012;183:128-34.
182. Miranda EF, Leal-Junior EC, Marchetti PH, Dal Corso S. Effects of light-
emitting diodes on muscle fatigue and exercise tolerance in patients with COPD:
study protocol for a randomized controlled trial. Trials 2013;14:134.
183. Mochizuki H, Nanjo Y, Kawate E, Yamazaki M, Tsuda Y, Takahashi H.
beta2-adrenergic receptor haplotype may be associated with susceptibility to
desensitization to long-acting beta2-agonists in COPD patients. Lung
2012;190:411-7.
184. Mohamed Hoesein FA, Zanen P, Sachs AP, Verheij TJ, Lammers JW,
Broekhuizen BD. Spirometric thresholds for diagnosing COPD: 0.70 or LLN, pre-
or post-dilator values? Copd 2012;9:338-43.
185. Moretto N, Bertolini S, Iadicicco C, et al. Cigarette smoke and its
component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2
signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol
2012;303:L929-38.
186. Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR. A pilot study
of an Internet walking program and pedometer in COPD. Respir Med
2012;106:1342-50.
187. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy
improves lung function, exercise capacity and life quality of COPD patients. Adv
Exp Med Biol 2013;756:23-8.
188. Murphy PB, Brignall K, Moxham J, Polkey MI, Davidson AC, Hart N. High
pressure versus high intensity noninvasive ventilation in stable hypercapnic
chronic obstructive pulmonary disease: a randomized crossover trial. Int J Chron
Obstruct Pulmon Dis 2012;7:811-8.
189. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-
acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2012;9:CD006829.
190. Nelson SB, LaVange LM, Nie Y, et al. Questionnaires and pocket
spirometers provide an alternative approach for COPD screening in the general
population. Chest 2012;142:358-66.
191. Nield M, Hoo GW. Real-time telehealth for COPD self-management using
Skype. Copd 2012;9:611-9.
192. Nishimura K, Nishimura T, Oga T. Streptococcus pneumoniae urinary
antigen test and acute exacerbations of chronic obstructive pulmonary disease.
Copd 2012;9:344-51.
193. Nowak D, Ehlken B, Kotchie R, Wecht S, Magnussen H. [Roflumilast in
combination with long-acting bronchodilators in the management of patients with
severe and very severe COPD. A cost-effectiveness analysis for Germany].
Dtsch Med Wochenschr 2013;138:119-25.
194. Nyberg A, Lindstrom B, Wadell K. Assessing the effect of high-repetitive
single limb exercises (HRSLE) on exercise capacity and quality of life in patients
with chronic obstructive pulmonary disease (COPD): study protocol for
randomized controlled trial. Trials 2012;13:114.
195. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological
characterisation of patients diagnosed with chronic obstructive pulmonary
disease in primary care. Thorax 2000;55:635-42.
196. O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes
mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir
Med 2012;106:1487-93.
197. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic
obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv
Respir Dis 2013;7:13-24.
198. Oh YM, Bhome AB, Boonsawat W, et al. Characteristics of stable chronic
obstructive pulmonary disease patients in the pulmonology clinics of seven Asian
cities. Int J Chron Obstruct Pulmon Dis 2013;8:31-9.
199. Oliveira MG, Nery LE, Santos-Silva R, et al. Is portable monitoring
accurate in the diagnosis of obstructive sleep apnea syndrome in chronic
pulmonary obstructive disease? Sleep Med 2012;13:1033-8.
200. Ospina MB, Voaklander DC, Stickland MK, King M, Senthilselvan A, Rowe
BH. Prevalence of asthma and chronic obstructive pulmonary disease in
Aboriginal and non-Aboriginal populations: a systematic review and meta-
analysis of epidemiological studies. Can Respir J 2012;19:355-60.
201. Palkovits S, Lasta M, Boltz A, et al. Measurement of retinal oxygen
saturation in patients with chronic obstructive pulmonary disease. Invest
Ophthalmol Vis Sci 2013;54:1008-13.
202. Pan L, Guo YZ, Yan JH, Zhang WX, Sun J, Li BW. Does upper extremity
exercise improve dyspnea in patients with COPD? A meta-analysis. Respir Med
2012;106:1517-25.
203. Park JS, Lim HJ, Cho YJ, Lee JH, Yoon HI, Lee CT. Udenafil improves
exercise capacity in patients with chronic obstructive pulmonary disease: a
prospective study. Copd 2012;9:499-504.
204. Parker DR, Eaton CB, Ahern DK, et al. The study design and rationale of
the randomized controlled trial: translating COPD guidelines into primary care
practice. BMC Fam Pract 2013;14:56.
205. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation
indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2004;170:400-7.
206. Pedone C, Chiurco D, Scarlata S, Incalzi RA. Efficacy of multiparametric
telemonitoring on respiratory outcomes in elderly people with COPD: a
randomized controlled trial. BMC Health Serv Res 2013;13:82.
207. Pinnock H, Hanley J, McCloughan L, et al. Effectiveness of telemonitoring
integrated into existing clinical services on hospital admission for exacerbation of
chronic obstructive pulmonary disease: researcher blind, multicentre, randomised
controlled trial. Bmj 2013;347:f6070.
208. Piquilloud L, Tassaux D, Bialais E, et al. Neurally adjusted ventilatory
assist (NAVA) improves patient-ventilator interaction during non-invasive
ventilation delivered by face mask. Intensive Care Med 2012;38:1624-31.
209. Polatli M, Ben Kheder A, Wali S, et al. Chronic obstructive pulmonary
disease and associated healthcare resource consumption in the Middle East and
North Africa: the BREATHE study. Respir Med 2012;106 Suppl 2:S75-85.
210. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic
obstructive pulmonary disease: minimal clinically important difference for death
or hospitalization. Am J Respir Crit Care Med 2013;187:382-6.
211. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or
chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2012;8:CD001287.
212. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized,
double-blind, placebo-controlled study assessing the safety and tolerability of
regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J
Nucl Cardiol 2012;19:681-92.
213. Prieto Centurion V, Huang F, Naureckas ET, et al. Confirmatory
spirometry for adults hospitalized with a diagnosis of asthma or chronic
obstructive pulmonary disease exacerbation. BMC Pulm Med 2012;12:73.
214. Rabe KF, Fabbri LM, Vogelmeier C, et al. Seasonal distribution of COPD
exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.
Chest 2013;143:711-9.
215. Rahaghi FF, Sandhaus RA, Brantly ML, et al. The prevalence of alpha-1
antitrypsin deficiency among patients found to have airflow obstruction. Copd
2012;9:352-8.
216. Reed RM, Eberlein M, Girgis RE, et al. Coronary artery disease is under-
diagnosed and under-treated in advanced lung disease. Am J Med
2012;125:1228 e13- e22.
217. Rennard SI, Flavin SK, Agarwal PK, Lo KH, Barnathan ES. Long-term
safety study of infliximab in moderate-to-severe chronic obstructive pulmonary
disease. Respir Med 2013;107:424-32.
218. Rhee CK, Yoo KH, Lee JH, et al. Clinical characteristics of patients with
tuberculosis-destroyed lung. Int J Tuberc Lung Dis 2013;17:67-75.
219. Romagnoli I, Scano G, Binazzi B, et al. Effects of unsupported arm
training on arm exercise-related perception in COPD patients. Respir Physiol
Neurobiol 2013;186:95-102.
220. Roman M, Larraz C, Gomez A, et al. Efficacy of pulmonary rehabilitation
in patients with moderate chronic obstructive pulmonary disease: a randomized
controlled trial. BMC Fam Pract 2013;14:21.
221. Rosstad T, Garasen H, Steinsbekk A, Sletvold O, Grimsmo A.
Development of a patient-centred care pathway across healthcare providers: a
qualitative study. BMC Health Serv Res 2013;13:121.
222. Rujirojindakul P, Geater AF, McNeil EB, et al. Risk factors for reintubation
in the post-anaesthetic care unit: a case-control study. Br J Anaesth
2012;109:636-42.
223. Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic
obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon
Dis 2012;7:457-94.
224. Sanders C, Rogers A, Bowen R, et al. Exploring barriers to participation
and adoption of telehealth and telecare within the Whole System Demonstrator
trial: a qualitative study. BMC Health Serv Res 2012;12:220.
225. Santus P, Buccellati C, Centanni S, et al. Bronchodilators modulate
inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res
2012;66:343-8.
226. Sava F, Perrault H, Brouillard C, et al. Detecting improvements in dyspnea
in COPD using a three-minute constant rate shuttle walking protocol. Copd
2012;9:395-400.
227. Sayiner A, Alzaabi A, Obeidat NM, et al. Attitudes and beliefs about
COPD: data from the BREATHE study. Respir Med 2012;106 Suppl 2:S60-74.
228. Scherr A, Schafroth Torok S, Jochmann A, et al. Response to add-on
inhaled corticosteroids in COPD based on airway hyperresponsiveness to
mannitol. Chest 2012;142:919-26.
229. Schlosser T, Burbelko M, Ulrich M, et al. [Percutaneous arteriovenous
shunting in patients with severe COPD: a new interventional radiological
treatment]. Rofo 2013;185:247-52.
230. Segrelles Calvo G, Zamora Garcia E, Giron Moreno R, et al. Non-invasive
ventilation in an elderly population admitted to a respiratory monitoring unit:
causes, complications and one-year evolution. Arch Bronconeumol 2012;48:349-
54.
231. Seo YB, Hong KW, Kim IS, et al. Effectiveness of the influenza vaccine at
preventing hospitalization due to acute lower respiratory infection and
exacerbation of chronic cardiopulmonary disease in Korea during 2010-2011.
Vaccine 2013;31:1426-30.
232. Seymour JM, Ward K, Raffique A, et al. Quadriceps and ankle dorsiflexor
strength in chronic obstructive pulmonary disease. Muscle Nerve 2012;46:548-
54.
233. Shelesky G, D'Amico F, Marfatia R, Munshi A, Wilson SA. Does weekly
direct observation and formal feedback improve intern patient care skills
development? A randomized controlled trial. Fam Med 2012;44:486-92.
234. Short PM, Williamson PA, Lipworth BJ. Effects of extra-fine inhaled and
oral corticosteroids on alveolar nitric oxide in COPD. Lung 2012;190:395-401.
235. Shukla Y, Wheatley A, Kirby M, et al. Hyperpolarized 129Xe magnetic
resonance imaging: tolerability in healthy volunteers and subjects with pulmonary
disease. Acad Radiol 2012;19:941-51.
236. Siddique HH, Olson RH, Parenti CM, et al. Randomized trial of pragmatic
education for low-risk COPD patients: impact on hospitalizations and emergency
department visits. Int J Chron Obstruct Pulmon Dis 2012;7:719-28.
237. Siedlinski M, Tingley D, Lipman PJ, et al. Dissecting direct and indirect
genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility.
Hum Genet 2013;132:431-41.
238. Singh D, Kampschulte J, Wedzicha JA, et al. A trial of
beclomethasone/formoterol in COPD using EXACT-PRO to measure
exacerbations. Eur Respir J 2013;41:12-7.
239. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-
ischaemic effects of inhaled anticholinergic medications. Thorax 2013;68:114-6.
240. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E,
Navarro M, Ochando R. Severe acute exacerbations and mortality in patients
with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
241. Sorensen D, Frederiksen K, Groefte T, Lomborg K. Nurse-patient
collaboration: a grounded theory study of patients with chronic obstructive
pulmonary disease on non-invasive ventilation. Int J Nurs Stud 2013;50:26-33.
242. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK.
Association between beta-blocker therapy and outcomes in patients hospitalised
with acute exacerbations of chronic obstructive lung disease with underlying
ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84.
243. Stewart JI, Moyle S, Criner GJ, et al. Automated telecommunication to
obtain longitudinal follow-up in a multicenter cross-sectional COPD study. Copd
2012;9:466-72.
244. Strasser B, Siebert U, Schobersberger W. Effects of resistance training on
respiratory function in patients with chronic obstructive pulmonary disease: a
systematic review and meta-analysis. Sleep Breath 2013;17:217-26.
245. Sugawara K, Takahashi H, Kashiwagura T, et al. Effect of anti-
inflammatory supplementation with whey peptide and exercise therapy in patients
with COPD. Respir Med 2012;106:1526-34.
246. Sundh J, Janson C, Lisspers K, Montgomery S, Stallberg B. Clinical
COPD Questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon
Dis 2012;7:833-42.
247. Tageldin MA, Nafti S, Khan JA, et al. Distribution of COPD-related
symptoms in the Middle East and North Africa: results of the BREATHE study.
Respir Med 2012;106 Suppl 2:S25-32.
248. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and
repeat doses of inhaled umeclidinium in patients with chronic obstructive
pulmonary disease: two randomised studies. Eur J Pharmacol 2013;701:40-8.
249. Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of
bronchodilator responsiveness: results from the Burden of Obstructive Lung
Disease study. Thorax 2012;67:718-26.
250. Tashkin DP, Rabinoff M, Noble EP, Ritchie TL, Simmons MS, Connett J.
Association of dopamine-related gene alleles, smoking behavior and decline in
FEV1 in subjects with COPD: findings from the lung health study. Copd
2012;9:620-8.
251. Tashkin DP, Wang HJ, Halpin D, et al. Comparison of the variability of the
annual rates of change in FEV(1) determined from serial measurements of the
pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD:
results of the lung health study. Respir Res 2012;13:70.
252. Thoonsen B, Engels Y, van Rijswijk E, et al. Early identification of
palliative care patients in general practice: development of RADboud indicators
for PAlliative Care Needs (RADPAC). Br J Gen Pract 2012;62:e625-31.
253. Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and
the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin
2012;28:1959-67.
254. To Y, Kinoshita M, Lee SH, et al. Assessing efficacy of indacaterol in
moderate and severe COPD patients: a 12-week study in an Asian population.
Respir Med 2012;106:1715-21.
255. Trivedi RB, Bryson CL, Udris E, Au DH. The influence of informal
caregivers on adherence in COPD patients. Ann Behav Med 2012;44:66-72.
256. Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable
COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Chest 2013;144:106-18.
257. Tseng CM, Chen YT, Ou SM, et al. The effect of cold temperature on
increased exacerbation of chronic obstructive pulmonary disease: a nationwide study.
PLoS One 2013;8:e57066.
258. Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies
perturbations in amino acid metabolism that sub-classify patients with COPD. Mol
Biosyst 2012;8:3125-33.
259. Uzaslan E, Mahboub B, Beji M, et al. The burden of chronic obstructive
pulmonary disease in the Middle East and North Africa: results of the BREATHE study.
Respir Med 2012;106 Suppl 2:S45-59.
260. van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with
two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv 2013;10:1023-
31.
261. van Dijk WD, Heijdra Y, Lenders JW, et al. Cigarette smoke retention and
bronchodilation in patients with COPD. A controlled randomized trial. Respir Med
2013;107:112-9.
262. Viggers H, Howden-Chapman P, Ingham T, et al. Warm homes for older people:
aims and methods of a randomised community-based trial for people with COPD. BMC
Public Health 2013;13:176.
263. Vijayasaratha K, Stockley RA. Relationship between frequency, length, and
treatment outcome of exacerbations to baseline lung function and lung density in alpha-1
antitrypsin-deficient COPD. Int J Chron Obstruct Pulmon Dis 2012;7:789-96.
264. Vogelmeier C, Fabbri LM, Rabe KF, et al. Effect of tiotropium vs. salmeterol on
exacerbations: GOLD II and maintenance therapy naive patients. Respir Med
2013;107:75-83.
265. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily
QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic
obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel
group study. Lancet Respir Med 2013;1:51-60.
266. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA.
Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane
Database Syst Rev 2012;12:CD010257.
267. Voncken-Brewster V, Tange H, de Vries H, Nagykaldi Z, Winkens B, van der
Weijden T. A randomised controlled trial testing a web-based, computer-tailored self-
management intervention for people with or at risk for chronic obstructive pulmonary
disease: a study protocol. BMC Public Health 2013;13:557.
268. Wang H, Yang L, Zou L, et al. Association between chronic obstructive
pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-
analysis. PLoS One 2012;7:e46144.
269. Wang Y, Haugen T, Steihaug S, Werner A. Patients with acute exacerbation of
chronic obstructive pulmonary disease feel safe when treated at home: a qualitative study.
BMC Pulm Med 2012;12:45.
270. Wang Y, Lee JY, Michele T, Chowdhury BA, Gobburu JV. Limitations of model
based dose selection for indacaterol in patients with chronic obstructive pulmonary
disease. Int J Clin Pharmacol Ther 2012;50:622-30.
271. Wedzicha JA, Decramer M, Ficker JH, et al. Efficacy and safety of once-daily
QVA149 compared with twice-daily salmeterolfl uticasone in patients with chronic
obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel
group study. Lancet Respir Med 2013;1:199-209.
272. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD
frequent exacerbator phenotype. Chest 2013;143:1302-11.
273. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-
controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013;143:1590-
8.
274. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute
exacerbations of COPD. N Engl J Med 2012;367:913-21.
275. Wilk JB, Shrine NR, Loehr LR, et al. Genome-wide association studies identify
CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care
Med 2012;186:622-32.
276. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus
amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL
results. Eur Respir J 2012;40:17-27.
277. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk
of death in COPD. N Engl J Med 2013;369:1491-501.
278. Xie X, de Jong PA, Oudkerk M, et al. Morphological measurements in computed
tomography correlate with airflow obstruction in chronic obstructive pulmonary disease:
systematic review and meta-analysis. Eur Radiol 2012;22:2085-93.
279. Xie Y, Li JS, Yu XQ, et al. Effectiveness of Bufei Yishen Granule combined with
acupoint sticking therapy on quality of life in patients with stable chronic obstructive
pulmonary disease. Chin J Integr Med 2013;19:260-8.
280. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991.
281. Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2
polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J
2012;12:484-8.
282. Yu XQ, Li JS, Li SY, et al. Functional and psychosocial effects of pulmonary
Daoyin on patients with COPD in China: study protocol of a multicenter randomized
controlled trial. J Integr Med 2013;11:140-6.
283. Zainuldin R, Mackey MG, Alison JA. Prescription of walking exercise intensity
from the incremental shuttle walk test in people with chronic obstructive pulmonary
disease. Am J Phys Med Rehabil 2012;91:592-600.
284. Zeng XT, Tu ML, Liu DY, Zheng D, Zhang J, Leng W. Periodontal disease and
risk of chronic obstructive pulmonary disease: a meta-analysis of observational studies.
PLoS One 2012;7:e46508.
285. Zwar NA, Hermiz O, Comino E, et al. Care of patients with a diagnosis of chronic
obstructive pulmonary disease: a cluster randomised controlled trial. Med J Aust
2012;197:394-8.
286. Zwerink M, van der Palen J, van der Valk P, Brusse-Keizer M, Effing T.
Relationship between daily physical activity and exercise capacity in patients with
COPD. Respir Med 2013;107:242-8.